US Bancorp DE Grows Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

US Bancorp DE raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHRGet Rating) by 6.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,073 shares of the biotechnology company’s stock after acquiring an additional 134 shares during the period. US Bancorp DE’s holdings in United Therapeutics were worth $434,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Fifth Third Bancorp raised its stake in shares of United Therapeutics by 2.2% during the 2nd quarter. Fifth Third Bancorp now owns 2,426 shares of the biotechnology company’s stock valued at $572,000 after buying an additional 53 shares during the last quarter. Hancock Whitney Corp raised its stake in shares of United Therapeutics by 0.4% during the 3rd quarter. Hancock Whitney Corp now owns 12,183 shares of the biotechnology company’s stock valued at $2,550,000 after buying an additional 53 shares during the last quarter. Arizona State Retirement System raised its stake in shares of United Therapeutics by 0.5% during the 2nd quarter. Arizona State Retirement System now owns 12,231 shares of the biotechnology company’s stock valued at $2,882,000 after buying an additional 57 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of United Therapeutics by 0.4% during the 2nd quarter. Victory Capital Management Inc. now owns 15,932 shares of the biotechnology company’s stock valued at $3,754,000 after buying an additional 58 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of United Therapeutics by 0.5% in the 1st quarter. Federated Hermes Inc. now owns 13,603 shares of the biotechnology company’s stock valued at $2,441,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 95.63% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on UTHR. UBS Group began coverage on United Therapeutics in a research note on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price target for the company. Wedbush lifted their price target on United Therapeutics from $250.00 to $305.00 in a research note on Thursday, November 3rd. Morgan Stanley lifted their price target on United Therapeutics from $322.00 to $330.00 and gave the company an “overweight” rating in a research note on Tuesday, December 6th. HC Wainwright lifted their price target on United Therapeutics from $255.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, November 3rd. Finally, JPMorgan Chase & Co. lifted their price target on United Therapeutics from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $283.64.

United Therapeutics Trading Up 0.6 %

Shares of United Therapeutics stock opened at $261.70 on Monday. The stock has a market cap of $11.93 billion, a P/E ratio of 17.80, a P/E/G ratio of 1.55 and a beta of 0.62. The stock’s 50 day simple moving average is $270.84 and its 200-day simple moving average is $241.24. United Therapeutics Co. has a 1-year low of $158.38 and a 1-year high of $283.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39.

United Therapeutics (NASDAQ:UTHRGet Rating) last issued its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, topping the consensus estimate of $3.57 by $1.34. The business had revenue of $516.00 million for the quarter, compared to analysts’ expectations of $492.92 million. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. Analysts predict that United Therapeutics Co. will post 16.57 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the transaction, the executive vice president now directly owns 36,397 shares in the company, valued at approximately $7,145,095.07. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Nilda Mesa sold 290 shares of United Therapeutics stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $268.57, for a total transaction of $77,885.30. Following the sale, the director now owns 6,180 shares of the company’s stock, valued at approximately $1,659,762.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 12,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the sale, the executive vice president now directly owns 36,397 shares in the company, valued at approximately $7,145,095.07. The disclosure for this sale can be found here. Insiders have sold a total of 207,390 shares of company stock worth $54,841,715 in the last ninety days. Insiders own 12.40% of the company’s stock.

United Therapeutics Company Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRGet Rating).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.